NCI selects ATCC to provide end-to-end cancer epidemiology services

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

NCI awarded ATCC a five-year indefinite-delivery/indefinite-quantity contract to support the Division of Cancer Epidemiology and Genetics’ Molecular Epidemiology Assay Support program.

DCEG’s mission is to conduct population and multidisciplinary research to discover the genetic and environmental determinants of cancer and new approaches to cancer prevention. The MEAS program provides support services for studies on the genetic and other cellular events that influence the onset of different types of cancer.

Under the contract, ATCC will provide collection supplies to study sites; perform aliquoting and advanced molecular assays; and provide short-term storage for human biospecimens and environmental samples obtained through family and population-based collection efforts, both domestically and internationally. ATCC will track all specimens using a customized biospecimen inventory and resource management system, ensuring that specimens are safeguarded appropriately for use in long-term epidemiology research projects.

“We understand that the proper collection, tracking and storage of specimens is of critical importance to cancer research, and take pride in maintaining and distributing these unique samples to the global research community,” said Joseph Leonelli, vice president for ATCC’s Microbiology and Government Solutions business.

Table of Contents

YOU MAY BE INTERESTED IN

Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings. 
At the 2026 Annual Meeting of the American Society of Clinical Oncology in Chicago, results from the phase III HARMONi-6 trial were presented at the plenary session and published simultaneously in The Lancet. The HARMONi-6 trial tested a novel bispecific antibody that engages PD-1 and VEGF (ivonescimab), given with platinum-doublet chemotherapy to patients with previously untreated advanced squamous non-small cell lung cancer. 
In 2026, more than 900 million people are estimated to be regularly using generative artificial intelligence—computer systems capable of creating human-like text, images, audio, video, and other original content. AI is becoming integrated into nearly every aspect of daily life. Health care is no exception. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login